Nowadays, prostate-specific antigen (PSA) blood screening tests, together with clinical T-stage and Gleason score are the standard tests to discriminate patients with low, intermediate or high risk to suffer PCa [1]. The gene discussed is KLK3; the disease is posterior cortical atrophy.